Free Trial

Syros Pharmaceuticals Q1 2024 Earnings Report

Syros Pharmaceuticals logo
$0.03 0.00 (-8.33%)
As of 12:31 PM Eastern

Syros Pharmaceuticals EPS Results

Actual EPS
-$0.79
Consensus EPS
-$0.89
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.85

Syros Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Syros Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Remove Ads

Syros Pharmaceuticals Earnings Headlines

Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
See More Syros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Syros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syros Pharmaceuticals and other key companies, straight to your email.

About Syros Pharmaceuticals

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

View Syros Pharmaceuticals Profile

More Earnings Resources from MarketBeat